Rivastigmine
As of the edition of 20 October 2026, Rivastigmine is a small molecule: marketed, first approved in 1997 (CH); acts on ACHE and BCHE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Exelon
- First approved
- 31 July 1997 (CH)
- Approvals on record
- 20 in 5 regions
- Holder of the most recent approval
- Towa Pharmaceutical Co., Ltd.; 10 holders in all
- Withdrawn from market
- 19 August 2014 (in some regions)
- Registered trials
- 67, 8 stopped early
- Disease areas
- Nervous system; Mental health; Heart and blood vessels; Injuries; Inherited and neonatal; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Rivastigmine.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 4 | 0 | 1 |
| Phase 1 | 7 | 7 | 0 | 0 |
| Phase 2 | 5 | 2 | 2 | 0 |
| Phase 3 | 17 | 14 | 0 | 3 |
| Phase 4 | 30 | 23 | 1 | 4 |
| All trials | 67 |